Biomarkers in patients with mucopolysaccharidosis type II and IV

被引：45

作者：

Fujitsuka, Honoka ^{[1
,2
]}

Sawamoto, Kazuki ^{[1
]}

Peracha, Hira ^{[1
,3
]}

Mason, Robert W. ^{[1
,3
]}

Mackenzie, William ^{[1
]}

Kobayashi, Hironori ^{[4
]}

Yamaguchi, Seiji ^{[4
]}

Suzuki, Yasuyuki ^{[2
]}

Orii, Kenji ^{[5
]}

Orii, Tadao ^{[5
]}

Fukao, Toshiyuki ^{[5
]}

Tomatsu, Shunji ^{[1
,4
,5
,6
]}

机构：

[1] Nemours Alfred I DuPont Hosp Children, Wilmington, DE 19899 USA

[2] Gifu Univ, Med Educ Dev Ctr, Gifu, Japan

[3] Univ Delaware, Dept Biol Sci, Newark, DE USA

[4] Shimane Univ, Dept Pediat, Matsue, Shimane, Japan

[5] Gifu Univ, Grad Sch Med, Dept Pediat, Gifu, Japan

[6] Thomas Jefferson Univ, Dept Pediat, Philadelphia, PA 19107 USA

来源：

MOLECULAR GENETICS AND METABOLISM REPORTS | 2019年 / 19卷

基金：

美国国家卫生研究院;

关键词：

Morquio syndrome; Hunter syndrome; Glycosaminoglycans; Cytokines; Inflammation; BONE-MARROW-TRANSPLANTATION; ENZYME REPLACEMENT THERAPY; STEM-CELL TRANSPLANTATION; KERATAN SULFATE; HEPARAN-SULFATE; MATRIX METALLOPROTEINASES; GLYCOSAMINOGLYCAN LEVELS; INFLAMMATORY CYTOKINES; TRACHEAL OBSTRUCTION; JOINT DISEASE;

D O I：

10.1016/j.ymgmr.2019.100455

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Glycosaminoglycans (GAGs), dermatan sulfate (DS), heparan sulfate (HS), and keratan sulfate (KS), are the primary biomarkers in patients with mucopolysaccharidoses (MPS); however, little is known about other biomarkers. To explore potential biomarkers and their correlation with GAGs, blood samples were collected from 46 MPS II patients, 34 MPS IVA patients, and 5 MPS IVB patients. We evaluated the levels of 8 pro-inflammatory factors (EGF, IL-1 beta, IL-6, MIP-1 alpha, TNF-alpha, MMP-1, MMP-2, and MMP-9), collagen type II, and DS, HS (HS0S, HSNS), and KS (mono-sulfated, di-sulfated) in blood. Eight biomarkers measured were significantly elevated in untreated MPS II patients, compared with those in normal controls: EGF, IL-1 beta, IL-6, HS0S, HSNS, DS, mono-sulfated KS, and di-sulfated KS. The same eight biomarkers remained elevated in ERT-treated patients. However, only three biomarkers remained elevated in post-HSCT MPS II patients: EGF, mono-sulfated KS, and di-sulfated KS. Post-HSCT patients with MPS II showed that IL-1 beta and IL-6 were normalized as HS and DS levels decreased. Eight biomarkers were significantly elevated in untreated MPS IVA patients: EGF, IL-1 beta, IL-6, MIP-1 alpha, MMP-9, HSNS, mono-sulfated KS, and di-sulfated KS, and four biomarkers were elevated in MPS IVA patients under ERT: IL-6, TNF-alpha, mono-sulfated KS, and di-sulfated KS. There was no reduction of KS in the ERT-treated MPS IVA patient, compared with untreated patients. Two biomarkers were significantly elevated in untreated MPS IVB patients: IL-6 and TNF-alpha. Reversely, collagen type II level was significantly decreased in untreated and ERT-treated MPS II patients and untreated MPS IVA patients. In conclusion, selected pro-inflammatory factors can be potential biomarkers in patients with MPS II and IV as well as GAGs levels.

引用

页数：9

共 50 条

[41] Evaluation of Two Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis Type II
Herbst, Zackary M.
Urdaneta, Leslie
Klein, Terri
Burton, Barbara K.
Basheeruddin, Khaja
Liao, Hsuan-Chieh
Fuller, Maria
Gelb, Michael H.
INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2022, 8 (01)
[42] Identification of gangliosides and ceramides as biomarkers for mucopolysaccharidosis type II (hunter syndrome) through untargeted lipidomic analysis
Farjallah, Asma
Maranda, Bruno
Giugliani, Roberto
Auray-Blais, Christiane
METABOLOMICS, 2025, 21 (02)
[43] Mucopolysaccharidosis type II (MPS II): Evaluate of food intakes in patients on enzyme replacement therapy
Oliveira, R. B.
Frangipani, B. J.
Lauandos, J. R.
Micheletti, C.
Silveira, M. T.
Vertemati, T.
Martins, A. M.
JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 100 - 100
[44] MUCOPOLYSACCHARIDOSIS TYPE II: A CLINICAL STUDY OF 77 SOUTH-AMERICAN PATIENTS
Schwartz, I
Ribeiro, M.
Mota, J.
Toralles, M.
Correia, P.
Horovitz, D.
Santos, E.
Monlleo, I
Fett-Conte, A.
Oliveira, S. R.
Norato, D.
Paula, A.
Kim, C.
Duarte, A.
Boy, R.
Valadares, E.
De Michelena, M.
Mabe, P.
Martinhago, C.
Pina-Neto, J.
Kok, F.
Leistner, S.
Burin, M.
Giugliani, R.
JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 188 - 188
[45] Identification of 11 novel mutations in 49 Korean patients with mucopolysaccharidosis type II
Sohn, Y. B.
Ki, C-S
Kim, C-H
Ko, A-R
Yook, Y-J
Lee, S-J
Kim, S. J.
Park, S. W.
Yeau, S.
Kwon, E-K
Han, S. J.
Choi, E. W.
Lee, S-Y
Kim, J-W
Jin, D-K
CLINICAL GENETICS, 2012, 81 (02) : 185 - 190
[46] Safety Study of Sodium Pentosan Polysulfate for Adult Patients with Mucopolysaccharidosis Type II
Orii, Kenji
Lim, Alaena
Tomatsu, Shunji
Stapleton, Molly
Suzuki, Yasuyuki
Simonaro, Calogera M.
Schuchman, Edward H.
Fukao, Toshiyuki
Matsumoto, Tadashi
DIAGNOSTICS, 2019, 9 (04)
[47] The reliability of death certification in patients dying with mucopolysaccharidosis type II (Hunter syndrome)
Seshadri, D.
Jones, S.
Burt, K.
Lavery, L.
Wraith, J. E.
CLINICAL GENETICS, 2011, 79 (06) : 599 - 600
[48] Orthopedic manifestations in patients with mucopolysaccharidosis type II enrolled in the Hunter Outcome Survey
Link, Bianca
Botha, Jaco
Giugliani, Roberto
MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S65 - S65
[49] Allogeneic stem cell transplantation in patients with mucopolysaccharidosis type II (Morbus hunter)
Hartz, Bernd
Muschol, Nicole
Bleeke, Matthias
Schrum, Johanna
Mueller, Ingo
BONE MARROW TRANSPLANTATION, 2019, 54 : 547 - 548
[50] Bilateral hip replacement in three patients with lysosomal storage disease: Mucopolysaccharidosis type IV and Mucolipidosis type III
Lewis, J. R. Pryce
Gibson, P. H.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2010, 92B (02): : 289 - 292

← 1 2 3 4 5 →